Related Experiment Video

Updated: Feb 6, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.9K

Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection

Mitsuyoshi Suzuki, Kei Minowa1, Hitoshi Tajiri2

  • 1Department of Pediatrics, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan.

Annals of Hepatology
|August 27, 2018
PubMed

Insights

Interferon-based simeprevir therapy is effective and safe for children with genotype 1 hepatitis C virus. This treatment is an option where newer direct-acting antivirals are not yet available.

Area of Science:

  • Hepatology
  • Pediatric Infectious Diseases
  • Virology

Background:

  • Hepatitis C virus (HCV) infection in children requires effective treatment options.
  • Genotype 1 HCV is a common subtype requiring specific therapeutic strategies.
  • Direct-acting antivirals (DAAs) are emerging but not universally accessible for pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of interferon-based simeprevir therapy in pediatric patients with genotype 1 HCV infection.
  • To establish simeprevir as a viable treatment option for children in regions with limited DAA availability.

Main Methods:

  • Retrospective analysis of pediatric patients with genotype 1 HCV treated with interferon-based simeprevir.
  • Assessment of viral clearance, sustained virologic response (SVR), and adverse events.

Main Results:

  • Interferon-based simeprevir demonstrated high efficacy in achieving viral clearance and SVR in children.
  • The therapy was well-tolerated, with a manageable safety profile.

Conclusions:

  • Interferon-based simeprevir is a highly effective and tolerable treatment for pediatric genotype 1 HCV infection.
  • This regimen serves as a crucial therapeutic option for children in countries awaiting DAA approval.

Keywords:
Direct-acting antiviralsHyperbilirubinemiaPeginterferonRibavirinShorter treatment time

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.7K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
314
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
236
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
305
Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.2K
Viral Structure00:56

Viral Structure

Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
74.6K